Vancouver, British Columbia – TheNewswire – 29 August, 2024 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (the “Company” or “MindBio”), is pleased to provide an update to shareholders.
Chief Executive Officer Justin Hanka provides a video update discussing the Company’s clinical trials currently dosing and underway, results from completed trials and plans for the future.
The Company has successfully completed Phase 1 and Phase 2a Clinical Trials with positive readouts and new discoveries. In February 2024, MindBio completed its Phase 2a trial of MB22001 in patients with Major Depressive Disorder. In this open label trial, patients experienced a 60% drop in depressive symptoms and 53% of patients entering the trial with MDD, at week 8 were in remission from their depression with a mean 14.1 point drop in MADRS score (Montgomery-Asberg Depression Rating Scale). Prior trial results using MB22001 recorded statistically significant improvements in total sleep time and quality of sleep and statistically significant increases in subjective feelings of “Happiness”, “Social Connectivity”, “Energy”, “Creativity” and “Wellness” with reduced “Anger” and “Irritability”.
We have now discovered the antidepressant response is sustained at 1 month and 3 months post an 8 week treatment cycle. MB22001 is a promising and potential market disruptive medicine for treating depressive illness.
The Company is now running two significant Phase 2B clinical trials with dosing underway and a third Phase 2B trial that has now also been approved in women’s health. In a series of world firsts, each of these trials is approved for the take-home use of MB22001, a proprietary and self-titratable form of Lysergic Acid Diethylamide (LSD) designed for safe take home microdosing.
There are only a handful of public companies in the world that have progressed to Phase 2 and Phase 3 clinical trials in psychedelic medicines. MindBio is the most advanced clinical trial stage biopharma company listed on the Canadian Securities Exchange and the only company at this level that is not listed on a senior exchange.
The Company will provide further updates in due course.
For further information, please contact:
Justin Hanka, Chief Executive Officer
pr@hlthcommunications.com
About MindBio Therapeutics
MindBio is a leading biotech/biopharma company focused on creating novel and emerging treatments for mental health conditions and is conducting world first take-home Microdosing (MB22001) human clinical trials. MB22001 is MindBio’s lead candidate drug, a proprietary titratable form of Lysergic Acid Diethylamide (LSD) designed for take-home microdosing. MindBio is a leader in microdosing of psychedelic medicines and is advancing its drug and technology protocols through clinical trials. MindBio has developed a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development and digital therapeutics, has completed Phase 1 clinical trials in 80 healthy participants and has completed a Phase 2a clinical trial in patients with Major Depressive Disorder, both trials with positive top line data reported. Currently underway are two Phase 2B trials, one in cancer patients experiencing existential distress and another in patients with Major Depressive Disorder. MindBio invests in research that forms the basis for developing novel and clinically proven treatments including digital technologies and interventions to treat debilitating health conditions such as depression, anxiety and other related mental health conditions.